CalciMedica (CALC) Competitors $3.45 +0.10 (+2.99%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CALC vs. CARA, GOSS, INZY, CRBU, TNYA, NBTX, KYTX, SCPH, NKTX, and ACTUShould you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include Cara Therapeutics (CARA), Gossamer Bio (GOSS), Inozyme Pharma (INZY), Caribou Biosciences (CRBU), Tenaya Therapeutics (TNYA), Nanobiotix (NBTX), Kyverna Therapeutics (KYTX), scPharmaceuticals (SCPH), Nkarta (NKTX), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry. CalciMedica vs. Cara Therapeutics Gossamer Bio Inozyme Pharma Caribou Biosciences Tenaya Therapeutics Nanobiotix Kyverna Therapeutics scPharmaceuticals Nkarta Actuate Therapeutics Cara Therapeutics (NASDAQ:CARA) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability. Which has better earnings and valuation, CARA or CALC? CalciMedica has lower revenue, but higher earnings than Cara Therapeutics. CalciMedica is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCara Therapeutics$20.97M0.80-$118.51M-$1.75-0.17CalciMedicaN/AN/A-$34.36M-$1.08-3.19 Do analysts rate CARA or CALC? Cara Therapeutics presently has a consensus target price of $2.32, suggesting a potential upside of 660.66%. CalciMedica has a consensus target price of $19.33, suggesting a potential upside of 460.39%. Given Cara Therapeutics' higher probable upside, research analysts clearly believe Cara Therapeutics is more favorable than CalciMedica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00CalciMedica 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CARA or CALC more profitable? CalciMedica has a net margin of 0.00% compared to Cara Therapeutics' net margin of -1,099.76%. CalciMedica's return on equity of -164.24% beat Cara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cara Therapeutics-1,099.76% -367.97% -107.43% CalciMedica N/A -164.24%-103.53% Does the MarketBeat Community favor CARA or CALC? Cara Therapeutics received 652 more outperform votes than CalciMedica when rated by MarketBeat users. However, 93.75% of users gave CalciMedica an outperform vote while only 72.98% of users gave Cara Therapeutics an outperform vote. CompanyUnderperformOutperformCara TherapeuticsOutperform Votes66772.98% Underperform Votes24727.02% CalciMedicaOutperform Votes1593.75% Underperform Votes16.25% Which has more volatility and risk, CARA or CALC? Cara Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Do insiders & institutionals have more ownership in CARA or CALC? 44.7% of Cara Therapeutics shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by insiders. Comparatively, 41.6% of CalciMedica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer CARA or CALC? In the previous week, Cara Therapeutics and Cara Therapeutics both had 3 articles in the media. CalciMedica's average media sentiment score of 0.67 beat Cara Therapeutics' score of -0.18 indicating that CalciMedica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CalciMedica 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCalciMedica beats Cara Therapeutics on 11 of the 16 factors compared between the two stocks. Ad Porter & CompanyFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Get CalciMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALC vs. The Competition Export to ExcelMetricCalciMedicaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.16M$6.48B$5.07B$8.89BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-3.194.4283.5712.93Price / SalesN/A375.031,220.3088.33Price / CashN/A52.5939.4636.25Price / Book5.1510.126.936.25Net Income-$34.36M$153.61M$119.12M$225.93M7 Day Performance2.37%-2.00%-1.83%-1.32%1 Month Performance-16.26%-7.47%-3.64%0.60%1 Year Performance11.65%31.80%31.64%26.23% CalciMedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALCCalciMedica3.0723 of 5 stars$3.45+3.0%$19.33+460.4%+10.6%$45.16MN/A-3.1930CARACara Therapeutics3.9304 of 5 stars$0.31flat$2.32+660.7%-71.2%$16.51M$20.97M0.0055Analyst ForecastGOSSGossamer Bio4.4297 of 5 stars$0.70-2.8%$9.20+1,220.9%-16.9%$161.98MN/A0.00180INZYInozyme Pharma1.2302 of 5 stars$2.79-0.7%$15.71+463.2%-28.5%$180.51MN/A0.0050CRBUCaribou Biosciences2.9283 of 5 stars$1.96-1.5%$11.25+474.0%-64.7%$180.20M$34.48M0.00100TNYATenaya Therapeutics3.9666 of 5 stars$2.22-2.2%$14.75+564.4%+18.4%$179.83MN/A0.00110Gap UpNBTXNanobiotix2.3432 of 5 stars$4.07+7.7%$11.50+182.7%-33.5%$178.16M$39.18M0.00100Positive NewsKYTXKyverna Therapeutics2.8357 of 5 stars$4.12+1.0%$25.71+524.1%N/A$176.14M$7.03M0.0096Analyst ForecastAnalyst RevisionGap UpSCPHscPharmaceuticals3.8122 of 5 stars$3.36-4.5%$15.00+346.4%-40.2%$176.14M$13.59M0.0030Analyst RevisionNKTXNkarta2.2027 of 5 stars$2.50+0.8%$16.50+560.0%-4.4%$175.01MN/A-1.33140ACTUActuate TherapeuticsN/A$8.67-2.6%N/AN/A$173.83MN/A0.0010 Related Companies and Tools Related Companies Cara Therapeutics Alternatives Gossamer Bio Alternatives Inozyme Pharma Alternatives Caribou Biosciences Alternatives Tenaya Therapeutics Alternatives Nanobiotix Alternatives Kyverna Therapeutics Alternatives scPharmaceuticals Alternatives Nkarta Alternatives Actuate Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CALC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CALC Stock Alerts